1. Academic Validation
  2. Efficacy and mechanisms of concentrated growth factor on facial nerve rehabilitation in a rabbit model

Efficacy and mechanisms of concentrated growth factor on facial nerve rehabilitation in a rabbit model

  • Biomater Sci. 2025 Jan 20. doi: 10.1039/d4bm01454e.
Xiaochen Yang 1 Zhengyao Hou 2 Kexin Wang 1 3 Jieying Li 1 3 Wei Shang 1 Lin Wang 1 Kai Song 1
Affiliations

Affiliations

  • 1 Department of Oral and Maxillofacial Surgery, the Affiliated Hospital of Qingdao University, No. 16 Jiangsu Road, Qingdao 266000, Shandong, China. assongkai@163.com.
  • 2 Department of Obstetrics and Gynecology, Qingdao Hospital of Traditional Chinese Medicine, Qingdao Hiser Hospital, Shandong, China.
  • 3 School of Stomatology, Qingdao University, Shandong, China.
Abstract

Accelerated rehabilitation following facial nerve injury presents unique clinical challenges. This study evaluates the therapeutic effects of concentrated growth factor (CGF) on facial nerve recovery in a rabbit model and on RSC96 Schwann cells. Characterization of the CGF membrane (CGFM) revealed a three-dimensional fibrin network with embedded platelets, and representative growth factors, including TGF-β1, PDGF-BB, IGF-1, bFGF, and VEGF, were detected. In vivo, the Crush + CGFM group exhibited enhanced axon and myelin regeneration, increased Schwann cell proliferation, and improved facial nerve function compared to the Crush group. In vitro, CGF treatment significantly promoted the proliferation and migration of RSC96 cells and facilitated axon elongation in NG108-15 cells compared to controls. Mechanistically, CGF treatment led to a significant increase in PDGFRβ phosphorylation. Inhibition of this pathway with SU16f decreased Schwann cell activity and hindered overall nerve rehabilitation. These results underscore CGF's potential to accelerate nerve repair by promoting axon and myelin regeneration and enhancing Schwann cell biological activity, with the PDGFRβ pathway playing a crucial regulatory role. This study highlights CGF as a promising therapeutic strategy for improving facial nerve rehabilitation.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-108628
    99.09%, PDGFRβ Inhibitor